SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Introgen Therapeutics
An SI Board Since February 2004
Posts SubjectMarks Bans Symbol
802 21 0 INGN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromPosted
77<i>INGN..." lets hope that it will find support above the $5 level. &Jibacoa6/14/2004
76Zeta: Ian already answered your question about RAGL.<g> ( I have been runJibacoa6/10/2004
75Zeta, 1. RAGL = Regards and Good Luck. 2. If you haven't run across CTIC Ian@SI6/9/2004
74<<RAGL>> Bernard,I've been meaning to ask you what does that mezeta19616/9/2004
73INGN has been under pressure for the past several months because of its previousJibacoa6/9/2004
72<<Cheers>>> Yeah right... Gosh... Zetazeta19616/9/2004
71>>NEW YORK, June 9 (Reuters) - Shares of Introgen Therapeutics Inc. (Nasdatuck6/9/2004
70Thanks Filo...clears things up with me and Jibacoa!... asgt.org This intriguedzeta19615/22/2004
69Zeta -- Here is the relevant text from the WSJ article cited in the response toFiloF5/19/2004
68<i> Do you have a link? </i> It is on Page R1 of the WSJ of May 17,Jibacoa5/18/2004
67What????????? <<BTW, those that participate in the SI contest this year szeta19615/18/2004
66<<INGN was in yesterday's WSJ list of the best recommendations in 2003zeta19615/18/2004
65INGN was in yesterday's WSJ list of the best recommendations in 2003 by the Jibacoa5/18/2004
64The role of the host immune response and the E3 immunoregulatory genes of the huJibacoa5/18/2004
63Abstract for 009 An Oncolytic Adenovirus Vector Combining Enhanced Cell-to-Cellzeta19615/18/2004
62Feel like I'm talking to myself over here...hey...they say that those that dzeta19615/17/2004
61INGN PR regarding 007 and 009 Seems the same news as was put out by the LA Timezeta19615/17/2004
60Introgen getting some ink this w/e... latimes.com the above doesn't mentiozeta19615/15/2004
59Preclinicals for lung cancer and INGN 241(mda7) published... Watching this molezeta19615/13/2004
58Zeta, First I do appreciate the effort you made in giving such a complete respoIan@SI5/11/2004
57>>>>>>>Ouch!<<<<<<<<<< Actuazeta19615/11/2004
56I listened to the call. Ouch! As Howard Cosell may have said, these guys are aIan@SI5/11/2004
55Hi Zeta, I'm still haven't nibbled at this one. I'll probably listIan@SI5/11/2004
54Thanks Ian for posting these...I've never seen a startup with over 20 cliniczeta19615/11/2004
53Introgen Therapeutics Reports First Quarter 2004 Financial Results; Results forIan@SI5/11/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News